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Abstract 
Case report on t(6;17)(p21;p13) and acquisition of 
the Philadelphia chromosome translocation with 
p190 BCR-ABL1 transcript during the course of 
myelodysplastic syndrome. 
Clinics 
Age and sex 
47 years old male patient. 
Previous history 
Preleukemia The patient had thrombocytopenia for 
10 years (platelet counts ranged between 70x106/L 
to 130x106/L, for what he had never received any 
treatment; no previous malignancy; no inborn 
condition of note  
Organomegaly 
no hepatomegaly , no splenomegaly , no enlarged 
lymph nodes , no central nervous system 
involvement  
Blood 
WBC: 2.5X 109/l 
HB: 8.6g/dl 
Platelets: 6X 109/l 
Blasts: 43% 
Bone marrow: The bone marrow was hypocellular 
with 6.5% blasts at presentation. 7 months later, the 
patient MDS transformed to AML and his bone 
marrow biopsy showed markedly hypercellular 
marrow with 69% blasts (0.4% promyelocytes, 2.7% 
myelocytes, 1.1% neutrophils, 1.8% lymphocytes 




Acute myeloid leukemia without maturation 
Immunophenotype 
Myeloid immunophenotype, (positive for CD13, 
CD33, CD34, HLDR, CS45 and CD117) with 
aberrant expression of CD7. 
Diagnosis 
AML with myelodysplasia-related changes. 
Provisional entity: AML with BCR/ABL1 
Survival 
Date of diagnosis 
08-2011 
Treatment 
After the patient was diagnosed with MDS, therapy 
with decitabine was administrated but the patient 
remained cytopenic. At progression chemotherapy 
combined with imatinib (400 mg/day) was 
administrated that was escalated to 800 mg/day two 
weeks later. 
Complete remission: no   
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Status Alive 
Last follow up: 04-2012 
Survival 
7+ The patient had traveled to his native country for 
further treatment.months 
Karyotype 
Sample bone marrow 
Culture time 24h 
Banding G-banding 
Results 




[2]/46,XY [20 ] at transition 
 
Figure 1. Karyotype of the patient from the time of 
diagnosis showing the 47,XY,t(6;17)(p21;p13),+8. 
Other molecular cytogenetics technics 
Fluorescence in situ hybridization studies (FISH) 
were performed on slides prepared for cytogenetic 
analysis using a t(9;22) specific BCR/ABL dual 
color, dual fusion, CEP 8 and LSI P53 probes (Abott 
Molecular/Vysis, US). 
Other molecular cytogenetics results 
Breakpoint on 17p13 prompted us to search for 
deletion of the p53 gene at presentation; however 
fluorescence in situ hybridization with LSI p53 
probe revealed only the presence of 2 normal P53 
signals in 500 interphase cells. Hybridization with 
chromosome 8 centromeric probe showed extra 
chromosome +8 in 50 % of cells. FISH studies with 
BCR/ABL performed at transition revealed 60% 
positive cells while retrospective studies performed 
on stored bone marrow cells from MDS phase failed 
to detect either the Philadelphia chromosome, either 
the BCR/ABL1 rearrangement. 
Other Molecular Studies 
Technics: 
Molecular studies were performed from total RNA 
extracted from the bone marrow sample using the 
TriZol LS reagent (Invitrogen, US) according to the 
manufacturer's recommendations. cDNA was 
prepared from 2μg of total RNA with the Superscript 
II cDNA Synthesis Kit (Invitrogen, US) according to 
manufacturer's instructions. 
Results: 
Quantitative molecular studies performed with 
GeneXpert (Cepheid, US) were negative for the 
major BCR/ABL1 transcript. The absence of p210 
BCR-ABL1 transcript was confirmed by reverse 
transcription-polymerase chain reaction analysis; 
however it showed breakpoint cluster region 
rearrangement between exons e1 and a2, compatible 
with the minor p190 BCR/ABL1 transcript. 
Comments 
We described a rare t(6;17)(p21;p13) (La Starza et 
al., 26) in a patient diagnosed with myelodysplastic 
syndrome that terminated in AML associated with 
acquisition of the Philadelphia chromosome 
translocation and the p190 BCR-ABL1 transcript. 
The patient initially had thrombocytopenia for 10 
years, but developed MDS and at that time 
karyotyping revealed the chromosomal translocation 
t(6;17)(p21;p13) associated with an extra 
chromosome 8.  
The initial myelodysplastic syndrome terminated to 
acute myeloid leukemia, accompanied by an 
appearance of a new clone, characterized by a 
Philadelphia chromosome. Reverse transcription-
polymerase chain reaction analysis further revealed 
the presence of the minor p190 BCR-ABL1 
transcript. Developing a Philadelphia chromosome, 
considered a primary anomaly, during the course of 
MDS is extremely rare phenomenon, described only 
in few patients (Melo et al., 1994; Onozawa et al., 
2003; Advani et al., 2004; Keung et al., 2004). Our 
study illustrates that the Ph translocation may 
develop from an existing MDS clone, accompanying 
or perhaps inducing disease transformation. The 
availability of preleukemic MDS phase in our patient 
offers an unique opportunity to analyze the role of 
BCR-ABL1 in leukemogenesis and the evolution of 
leukemia clones in hematological malignancies. 
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Figure 2. (A) Representative metaphase of the patient from the time of transition showing the 
47,XY,t(6;17)(p21;p13),+8,t(9;22)(q34;q11) karyotype. (B) Fluorescence in situ hybridization with LSI BCR-ABL1 probe (Vysis, 
IL, US) showing the fusion BCR-ABL1 signal on der(9) and der(22) chromosomes. (C) Ethidium-bromide-stained agarose gel 
showing RT-PCR-amplified BCR-ABL1 chimaeric transcripts1. Lanes M, molecular weight marker; lane 1, e1a2 fusion in a 
patient; line 2, ABL internal control; line 3, e1a2-positive cell control; line 4, negative control; line 5, negative reaction with 
p210BCR/ABL primers in a patient; line 6, p210 CML positive control. 
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